Overview
Boxed Warning
FDA Black Box Warning
5.1 [see Warnings and Precautions ()] Natalizumab products increase the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of PML include the presence of anti-JCV a
Contraindications
When this intervention should not be used
• 5.1 [see Warnings and Precautions ()] TYRUKO is contraindicated in patients who have or have had progressive multifocal leukoencephalopathy (PML). • 5.5 [see Warnings and Precautions ()] TYRUKO is contraindicated in patients who have had a hypersensitivity reaction to natalizumab products or any o
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
Clinical Trials
11 trials linked to this intervention
Recent Trials
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Specialists
Providers who commonly manage this intervention
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Natalizumab (substance)
- SNOMED CT
- 414805007
- UMLS CUI
- C1172734
- RxNorm CUI
- 354770
- Labeler
- Sandoz Inc
Clinical Data
This intervention maps to 7 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.